WS Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

WS Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.2M	Buy	150,000 +20,000	+15%	+$2.5M	1.69%	20
2025 Q4	$15.9M	Buy	130,000 +53,543	+70%	+$6.14M	1.3%	23
2025 Q3	$7.66M	Hold	76,457	–	–	0.83%	31
2025 Q2	$6.34M	Hold	76,457	–	–	0.88%	29
2025 Q1	$6.2M	Sell	76,457 -23,543	-24%	-$2.1M	0.69%	26
2024 Q4	$9.01M	Hold	100,000	–	–	0.84%	27
2024 Q3	$9.88M	Hold	100,000	–	–	0.69%	31
2024 Q2	$9.27M	Sell	100,000 -25,000	-20%	-$2.24M	0.68%	35
2024 Q1	$11.9M	Sell	125,000 -25,000	-17%	-$2.32M	0.75%	32
2023 Q4	$13.4M	Hold	150,000	–	–	0.8%	34
2023 Q3	$11M	Buy	150,000 +30,000	+25%	+$2.4M	0.88%	34
2023 Q2	$9.98M	Sell	120,000 -80,000	-40%	-$6.69M	0.84%	33
2023 Q1	$15.2M	Buy	200,000 +100,000	+100%	+$8.3M	1.61%	19
2022 Q4	$8.3M	Hold	100,000	–	–	0.71%	35
2022 Q3	$7.93M	Sell	100,000 -70,000	-41%	-$5.9M	0.72%	32
2022 Q2	$12.6M	Buy	+170,000	New	+$12.8M	1.03%	22

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WS Management's XBI Position: Q1 2026 in Review

WS Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, buying an estimated $2.5M and bringing the position to 150,000 shares worth $19.2M. The position accounts for 1.69% of the portfolio, ranked #20.

WS Management first reported a position in XBI in Q2 2022 and has held it in 16 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

WS Management held 150,000 shares of State Street SPDR S&P Biotech ETF worth $19.2M as of Q1 2026.
WS Management bought 20,000 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $2.5M.
State Street SPDR S&P Biotech ETF made up 1.69% of WS Management's portfolio in Q1 2026, its #20 holding.
WS Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 16 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on WS Management's 13F filing for Q1 2026, filed 15 May 2026.